ASTRAZENECA PLC Form 6-K: Report of foreign private issuer
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2014-12-19: Form 6-K; Period of report 2014-12-19; Description LYNPARZA APPROVED BY THE US FDA; Document azn201412196k.htm.
- 2014-12-18: Form 6-K; Period of report 2014-12-18; Description LYNPARZA? APPROVED IN THE EUROPEAN UNION; Document azn201412186k.htm.
- 2014-12-09: Form 6-K; Period of report 2014-12-09; Description MOVENTIG APPROVED IN THE EU FOR OIC; Document azn201412096k.htm.
- 2014-12-05: Form 6-K; Period of report 2014-12-05; Description JURY VERDICT FAVOURS AZ IN NEXIUM LITIGATION; Document azn201412056k.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2014-12-19 | 6-K | 2014-12-19 | LYNPARZA APPROVED BY THE US FDA | azn201412196k.htm |
| 2014-12-18 | 6-K | 2014-12-18 | LYNPARZA? APPROVED IN THE EUROPEAN UNION | azn201412186k.htm |
| 2014-12-09 | 6-K | 2014-12-09 | MOVENTIG APPROVED IN THE EU FOR OIC | azn201412096k.htm |
| 2014-12-05 | 6-K | 2014-12-05 | JURY VERDICT FAVOURS AZ IN NEXIUM LITIGATION | azn201412056k.htm |
| 2014-12-02 | 6-K | 2014-12-01 | NEW DRUG APPLICATION FOR IRESSA ACCEPTED BY US FDA | azn201412026k.htm |
| 2014-12-01 | 6-K | 2014-12-01 | BLOCKLISTING INTERIM REVIEW | azn201412016k1.htm |
| 2014-12-01 | 6-K | 2014-12-01 | TOTAL VOTING RIGHTS | azn201412016k.htm |
| 2014-11-26 | 6-K/A | 2014-11-26 | POSITIVE RESULTS FROM BRODALUMAB PHASE III STUDY | azn201411266k.htm |
| 2014-11-24 | 6-K | 2014-11-24 | PUBLICATION OF FINAL TERMS | azn201411246k2.htm |
| 2014-11-24 | 6-K | 2014-11-24 | DUAKLIR GENUAIR APPROVED IN THE EU FOR COPD | azn201411246k.htm |
| 2014-11-19 | 6-K | 2014-11-19 | LAUNCH AND PRICING OF A ?750M BOND | azn201411196k.htm |
| 2014-11-18 | 6-K | 2014-11-18 | AZ STRATEGY ON TRACK TO DELIVER GROWTH AND VALUE | azn201411186k.htm |
| 2014-11-17 | 6-K | 2014-11-17 | PUBLICATION OF SUPPLEMENTARY PROSPECTUS | azn201411176k.htm |
| 2014-11-12 | 6-K | 2014-11-12 | AMGEN & AZ POSITIVE PHASE III BRODALUMAB RESULTS | azn201411126k.htm |
| 2014-11-10 | 6-K | 2014-11-10 | DIRECTOR/PDMR SHAREHOLDING | azn201411106k.htm |
| 2014-11-06 | 6-K | 2014-11-06 | ASTRAZENECA TO DIVEST MYALEPT TO AEGERION | azn201411066k1.htm |
| 2014-11-06 | 6-K | 2014-11-06 | 3RD QUARTER RESULTS | azn201411066k2.htm |
| 2014-11-06 | 6-K | 2014-11-06 | 3RD QUARTER RESULTS | azn201411066k.htm |
| 2014-11-05 | 6-K | 2014-11-05 | NOTICE OF RESULTS | azn201411056k.htm |
| 2014-11-04 | 6-K | 2014-11-04 | MEDIMMUNE ACQUIRES DEFINIENS | azn201411046k.htm |
| 2014-11-03 | 6-K | 2014-11-03 | TOTAL VOTING RIGHTS | azn201411036k2.htm |
| 2014-11-03 | 6-K | 2014-11-03 | AZ COMPLETES STRATEGIC TRANSACTION WITH ALMIRALL | azn201411036k.htm |
| 2014-10-30 | 6-K | 2014-10-30 | US FDA APPROVES ONCE-DAILY XIGDUO? XR TABLETS | azn201410306k.htm |
| 2014-10-24 | 6-K | 2014-10-24 | OLAPARIB RECEIVES POSITIVE CHMP OPINION | azn201410246k.htm |
| 2014-10-02 | 6-K | 2014-10-02 | DIRECTOR/PDMR SHAREHOLDING | azn201410026k.htm |
| 2014-10-01 | 6-K | 2014-10-01 | TOTAL VOTING RIGHTS | azn201410016k.htm |
| 2014-09-29 | 6-K | 2014-09-29 | ASTRAZENECA UPDATES ON ONCOLOGY PIPELINE AT ESMO | azn201409296k.htm |
| 2014-09-26 | 6-K | 2014-09-26 | POSITIVE CHMP OPINION FOR MOVENTIG (NALOXEGOL) | azn201409266k.htm |
| 2014-09-16 | 6-K | 2014-09-16 | FDA APPROVES MOVANTIK (NALOXEGOL) TABLETS | azn201409166k2.htm |
| 2014-09-16 | 6-K | 2014-09-16 | AZ AND LILLY ALLIANCE TO DEVELOP BACE INHIBITOR | azn201409166k.htm |
| 2014-09-10 | 6-K | 2014-09-10 | DIRECTOR/PDMR SHAREHOLDING | azn201409106k.htm |
| 2014-09-02 | 6-K | 2014-09-02 | TOTAL VOTING RIGHTS | azn201409026k.htm |
| 2014-08-19 | 6-K | 2014-08-14 | US DOJ CLOSES INVESTIGATION INTO PLATO | azn201408196k1.htm |
| 2014-08-19 | 6-K | 2014-08-14 | CAZ-AVI PHASE III RESULTS | azn201408196k.htm |
| 2014-08-14 | 6-K | 2014-08-14 | TRALOKINUMAB PHASE III START IN SEVERE ASTHMA | azn201408136k1.htm |
| 2014-08-13 | 6-K | 2014-08-13 | PHASE III RESULTS LESINURAD COMBINATION THERAPY | azn201408136k.htm |
| 2014-08-04 | 6-K | 2014-08-04 | DIRECTOR/PDMR SHAREHOLDING | azn201408046k.htm |
| 2014-08-01 | 6-K | 2014-08-01 | TOTAL VOTING RIGHTS | azn201408016k1.htm |
| 2014-08-01 | 6-K | 2014-08-01 | DIRECTOR/PDMR SHAREHOLDING | azn201408016k.htm |
| 2014-07-31 | 6-K | 2014-07-31 | ASTRAZENECA PIPELINE | azn201407316k.htm |
| 2014-07-31 | 6-K | 2014-07-31 | SECOND QUARTER & HALF YEAR RESULTS 2014 | azn201407316k1.htm |
| 2014-07-30 | 6-K | 2014-07-30 | NOTICE OF RESULTS | azn201407306k1.htm |
| 2014-07-30 | 6-K | 2014-07-30 | STRATEGIC RESPIRATORY TRANSACTION WITH ALMIRALL | azn201407306k.htm |
| 2014-07-01 | 6-K | 2014-07-01 | TOTAL VOTING RIGHTS | azn201407016k1.htm |
| 2014-07-01 | 6-K | 2014-07-01 | DIRECTOR/PDMR SHAREHOLDING | azn201407016k.htm |
| 2014-06-26 | 6-K | 2014-06-26 | DIRECTOR/PDMR SHAREHOLDING | azn201406266k2.htm |
| 2014-06-26 | 6-K | 2014-06-26 | FDA ADVISORY COMMITTEE VOTES ON OLAPARIB | azn201406266k.htm |
| 2014-06-24 | 6-K | 2014-06-24 | PUBLICATION OF PROSPECTUS | azn201406246k.htm |
| 2014-06-18 | 6-K | 2014-06-18 | HOLDING(S) IN COMPANY | azn201406186k2.htm |
| 2014-06-18 | 6-K | 2014-06-18 | DIRECTOR/PDMR SHAREHOLDING | azn201406186k1.htm |
| 2014-06-18 | 6-K | 2014-06-18 | DIRECTOR/PDMR SHAREHOLDING | azn201406186k.htm |
| 2014-06-13 | 6-K | 2014-06-13 | CLARIFICATION OF AXA SHAREHOLDING IN ASTRAZENECA | azn201406136k1.htm |
| 2014-06-13 | 6-K | 2014-06-13 | FDA ADCOM RECOMMENDS NO CV TRIAL FOR PAMORA | azn201406136k.htm |
| 2014-06-12 | 6-K | 2014-06-12 | ASTRAZENECA IN-LICENSES SYNAIRGEN'S SNG001 | azn201406126k.htm |
| 2014-06-11 | 6-K | 2014-06-11 | AZ TO PRESENT NEW DATA AT ADA | azn201406116k.htm |
| 2014-06-03 | 6-K/A | 2014-06-03 | ASTRAZENECA UPDATES ON ONCOLOGY PIPELINE AT ASCO | azn201406036ka.htm |
| 2014-06-03 | 6-K | 2014-06-03 | ASTRAZENECA UPDATES ON ONCOLOGY PIPELINE AT ASCO | azn201406036k.htm |
| 2014-06-02 | 6-K | 2014-06-02 | BLOCKLISTING INTERIM REVIEW | azn201406026k2.htm |
| 2014-06-02 | 6-K | 2014-06-02 | TOTAL VOTING RIGHTS | azn201406026k.htm |
| 2014-05-27 | 6-K | 2014-05-27 | STATEMENT REGARDING PFIZER WITHDRAWAL | azn201405276k.htm |
| 2014-05-23 | 6-K | 2014-05-23 | RULE 2.10 ANNOUNCEMENT | azn201405236k.htm |
| 2014-05-22 | 6-K | 2014-05-22 | RULE 2.10 ANNOUNCEMENT | azn201405226k.htm |
| 2014-05-21 | 6-K | 2014-05-21 | RULE 2.10 ANNOUNCEMENT | azn201405216k.htm |
| 2014-05-20 | 6-K | 2014-05-20 | CLARIFICATION REGARDING PFIZER STATEMENT | azn201405206k2.htm |
| 2014-05-20 | 6-K | 2014-05-20 | RULE 2.10 ANNOUNCEMENT | azn201405206k.htm |
| 2014-05-19 | 6-K | 2014-05-19 | RULE 2.10 ANNOUNCEMENT | azn201405196k2.htm |
| 2014-05-19 | 6-K | 2014-05-19 | ASTRAZENECA BOARD REJECTS PFIZER?S FINAL PROPOSAL | azn201405196k.htm |
| 2014-05-16 | 6-K | 2014-05-16 | RULE 2.10 ANNOUNCEMENT | azn201405166k.htm |
| 2014-05-15 | 6-K | 2014-05-15 | CONTINUING PROGRESS IN LATE STAGE PIPELINE | azn201405156k2.htm |
| 2014-05-15 | 6-K | 2014-05-15 | RULE 2.10 ANNOUNCEMENT | azn201405156k1.htm |
| 2014-05-15 | 6-K | 2014-05-15 | ASTRAZENECA ONCOLOGY PIPELINE UPDATE AHEAD OF ASCO | azn201405156k.htm |
| 2014-05-14 | 6-K | 2014-05-14 | RULE 2.10 ANNOUNCEMENT | azn201405146k1.htm |
| 2014-05-14 | 6-K | 2014-05-14 | MEDIMMUNE ANNOUNCES IMMUNO-ONCOLOGY COLLABORATION | azn201405146k.htm |
| 2014-05-13 | 6-K | 2014-05-13 | STATEMENT REGARDING PFIZER ANNOUNCEMENT | azn201405136k2.htm |
| 2014-05-13 | 6-K | 2014-05-13 | RULE 2.10 ANNOUNCEMENT | azn201405136k1.htm |
| 2014-05-13 | 6-K | 2014-05-13 | AZ PHASE III SAXA/DAPA RESULTS | azn201405136k.htm |
| 2014-05-12 | 6-K | 2014-05-12 | FORM 8 (OPD) PFIZER INC. | azn201405126k5.htm |
| 2014-05-12 | 6-K | 2014-05-12 | FORM 8 (OPD) ASTRAZENECA PLC | azn201405126k4.htm |
| 2014-05-12 | 6-K | 2014-05-12 | AZ ANNOUNCES RESULTS OF PHASE IIB STUDIES | azn201405126k3.htm |
| 2014-05-12 | 6-K | 2014-05-12 | AZ TO PRESENT DATA AT ATS 2014 | azn201405126k2.htm |
| 2014-05-12 | 6-K | 2014-05-12 | RULE 2.10 ANNOUNCEMENT | azn201405126k1.htm |
| 2014-05-12 | 6-K | 2014-05-12 | AMGEN & AZ BRODALUMAB PHASE III RESULTS | azn201405126k.htm |
| 2014-05-09 | 6-K | 2014-05-09 | RULE 2.10 ANNOUNCEMENT | azn201405096k.htm |
| 2014-05-08 | 6-K | 2014-05-08 | ASTRAZENECA INITIATES PHASE III STUDY FOR MEDI4736 | azn201405086k1.htm |
| 2014-05-08 | 6-K | 2014-05-08 | RULE 2.10 ANNOUNCEMENT | azn201405086k.htm |
| 2014-05-07 | 6-K | 2014-05-07 | HOLDING(S) IN COMPANY | azn201405076k1.htm |
| 2014-05-07 | 6-K | 2014-05-07 | RULE 2.10 ANNOUNCEMENT | azn201405076k.htm |
| 2014-05-06 | 6-K | 2014-05-06 | CHANGES TO MEMBERSHIP OF BOARD COMMITTEES | azn201405066k4.htm |
| 2014-05-06 | 6-K | 2014-05-06 | ASTRAZENECA ISSUES UPDATE ON STRATEGY | azn201405066k3.htm |
| 2014-05-06 | 6-K | 2014-05-06 | RULE 2.10 ANNOUNCEMENT | azn201405066k2.htm |
| 2014-05-06 | 6-K | 2014-05-06 | US FDA APPROVES EPANOVA | azn201405066k.htm |
| 2014-05-02 | 6-K | 2014-05-02 | ASTRAZENECA BOARD REJECTS PFIZER PROPOSAL | azn201405026k3.htm |
| 2014-05-02 | 6-K | 2014-05-02 | RULE 2.10 ANNOUNCEMENT | azn201405026k2.htm |
| 2014-05-02 | 6-K | 2014-05-02 | STATEMENT REGARDING PFIZER ANNOUNCEMENT | azn201405026k.htm |
| 2014-05-01 | 6-K | 2014-05-01 | RULE 2.10 ANNOUNCEMENT | azn201405016k1.htm |
| 2014-05-01 | 6-K | 2014-05-01 | TOTAL VOTING RIGHTS | azn201405016k.htm |
| 2014-04-30 | 6-K | 2014-04-30 | RULE 2.10 ANNOUNCEMENT | azn201404306k.htm |
| 2014-04-29 | 6-K | 2014-04-29 | RULE 2.10 ANNOUNCEMENT | azn201404296k.htm |
| 2014-04-28 | 6-K | 2014-04-28 | STATEMENT REGARDING PFIZER ANNOUNCEMENT | azn201404286k.htm |
| 2014-04-24 | 6-K | 2014-04-24 | RESULT OF AGM | azn201404246k3.htm |